Artículo

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024

Resumen

Programmed cell death-1 (PD-1) inhibitors and programmed cell death ligand 1 (PD-L1) inhibitors are considered effective alternatives for the primary treatment of recurrent metastatic cancers. However, they can induce various adverse events affecting multiple organ systems, potentially diminishing patients’ quality of life, and even leading to treatment interruptions. Adverse events related to PD-1/PD-L1 inhibitors differ from those associated with CTLA-4 inhibitors and are more commonly observed in the treatment of solid tumors. This study aimed to address the knowledge gap regarding adverse events related to PD-1/PD-L1 inhibitors. A visual bibliometric network was constructed using VOSviewer, CiteSpace, R software, and the Web of Science Core Collection (WoSCC) to quantitatively analyze this research field. Future research directions were also explored. The USA ranked first in publication count and total citations. Over time, publication types transitioned from case reports to clinical trials. Research on for nivolumab was the most prevalent. The spectrum of cancers treated by PD-1/PD-L1 inhibitors expanded beyond melanoma and lung cancer to include renal cell carcinoma, esophageal cancer, and others. Common adverse events included pneumonitis, myasthenia gravis, and vitiligo. There was a significant increase in multi-phase clinical trials and studies related to biomarkers. This study offers valuable insights for potential collaborators and institutions, highlighting trends in the study of adverse events related to PD-1/PD-L1 inhibitors. The management of these adverse events has become more refined and standardized. Biomarker research and multi-phase clinical trials are likely to be key areas of focus in future studies.
Song, Qingya (57895531700); Yu, Zongliang (57226322705); Lu, Wenping (57193354580); Zhuo, Zhili (57800465800); Chang, Lei (57801013200); Mei, Heting (57800829500); Cui, Yongjia (57801751200); Zhang, Dongni (57800829400)
PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
2025
10.1080/21645515.2024.2424611
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85214773513&doi=10.1080%2f21645515.2024.2424611&partnerID=40&md5=034ba2c7ea894ac8a0218ca061276dab
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China; Graduate School, Beijing University of Chinese Medicine, Beijing, China
All Open Access; Gold Open Access
Scopus
Artículo obtenido de:
Scopus
Fuente
0 0 votos
Califica el artículo
Subscribirse
Notificación de
Campus Samborondón
Vía Samborondón Km. 13.5
Call Center: 5150400
metricas@ecotec.edu.ec
Facebook Instagram Youtube

Mapa del sitio